According to a new U.S. Congressional Budget Office analysis, President Donald Trump’s 2026 budget plan proposes cuts to the National Institutes of Health that could significantly reduce the number of ...

Mass spectrometry is critical in drug discovery — but legacy systems, data silos, and poor metadata are slowing progress. This white paper, in partnership with Thermo Fisher, shares how experts from ...

Compass Pathways’ investigational psilocybin therapy COMP360 significantly eases symptoms in patients with treatment-resistant depression, clearing the way for regulatory discussions. A release from ...

JUNE 10, 2025 — UTSA researchers in the Max and Minnie Tomerlin Voelcker CIDD Preclinical Pharmacology Core for Accelerated Drug Discovery were recently awarded a competitive grant that will allow ...

These models demonstrate effects of similarity and proximity. Additionally, there has been an increase in the involvement of developing countries in the research and development of new biologic drugs ...

With pharmaceutical innovation representing one of the bright spots for positive change in health care, appreciating the impact of policy is key to a healthier and more competitive America.

Valinor Discovery, a company pioneering machine learning-powered simulation of therapeutic performance to derisk drug development, today exited stealth to an ...

Human infection challenge studies (HICs) are powerful in establishing early proof-of-concept for experimental drugs and understanding disease pathogenesis. A comprehensive assessment of HICs will ...

Sapient, a leader in multi-omics data generation for biomarker discovery and clinical insight delivery, has launched the next generation of its multi-omics a ...

In this interview, rare disease expert Oxana Iliach discusses challenges with rare disease drug development and how they can be addressed.

Biotech companies developing drugs for hard-to-treat diseases and other ailments are being forced to push back clinical trials and drug testing in the wake of mass layoffs at the Food and Drug ...

Clinical trials are vital to drug development but often face challenges such as slow patient recruitment, high costs, and suboptimal trial designs. Today, artificial intelligence (AI) and real ...